Document is current

Article History

Received: 27 April 2024

Accepted: 19 July 2024

First Online: 13 August 2024

Declarations

:

: The author declares no conflict of interest.

: The study was conducted in accordance with ethical principles and was approved by the Ethics Committee of Shandong Cancer Hospital and Institute. All the patients provided informed consent to participate in the study before undergoing percutaneous MWA treatment for hepatic malignant tumors. The research followed established ethical guidelines to ensure patient confidentiality, data integrity, and respect for individual rights. Participation in the study was voluntary, and patients were informed about the nature of the research, potential risks and benefits, and their right to withdraw at any time without any impact on their medical care. The study adhered to ethical standards to safeguard the well-being and rights of the participants involved.

: Written informed consent was obtained from the patient.